| 2026-03-16 |
详情>>
股本变动：
变动后总股本644.52万股
|
| 2026-03-16 |
详情>>
业绩披露：
2025年年报每股收益-4.74美元,归母净利润-3037.5万美元,同比去年增长-40.75%
|
| 2026-03-16 |
财报披露：
美东时间 2026-03-16 盘后发布财报
|
| 2025-11-10 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.19美元,归母净利润-1844.8万美元,同比去年增长-66.12%
|
| 2025-08-11 |
详情>>
业绩披露：
2025年中报每股收益-0.31美元,归母净利润-2989.3万美元,同比去年增长-265.26%
|
| 2025-05-12 |
详情>>
业绩披露：
2025年一季报每股收益-0.14美元,归母净利润-1354.1万美元,同比去年增长-200.24%
|
| 2025-04-08 |
股东大会：
将于2025-05-07召开股东大会
会议内容 ▼▲
- 1.To elect the seven directors named in the Proxy Statement to hold office until the 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified.
2.To approve an amendment and restatement of the Company’s Amended and Restated 2014 Omnibus Incentive Plan to increase the number of shares available for issuance thereunder.
3.To approve, on an advisory basis, the compensation of the Company’s named executive officers.
4.To approve an amendment to the Company’s Certificate of Incorporation to effect a reverse stock split at a ratio of not less than 1-for-2 and not greater than 1-for-15, inclusive.
5.To ratify the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.
6.To transact such other business as may properly come before the meeting or any adjournments or postponements thereof.
|
| 2025-03-12 |
详情>>
业绩披露：
2024年年报每股收益-0.23美元,归母净利润-2158.1万美元,同比去年增长93.50%
|
| 2024-11-12 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.12美元,归母净利润-1110.5万美元,同比去年增长95.96%
|
| 2024-08-07 |
详情>>
业绩披露：
2024年中报每股收益-0.09美元,归母净利润-818.4万美元,同比去年增长-264.14%
|
| 2024-05-06 |
详情>>
业绩披露：
2024年一季报每股收益-0.05美元,归母净利润-451万美元,同比去年增长-29.45%
|
| 2024-04-19 |
股东大会：
将于2024-05-23召开股东大会
会议内容 ▼▲
- 1.To elect the six directors named in the Proxy Statement to hold office until the 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified.
2.To approve an amendment and restatement of the Company’s Amended and Restated 2014 Omnibus Incentive Plan, including to increase the number of shares available for issuance thereunder.
3.To approve, on an advisory basis, the compensation of the Company’s named executive officers.
4.To approve an amendment to the Company’s Certificate of Incorporation to reflect recently adopted Delaware law provisions regarding officer exculpation.
5.To approve an amendment to the Certificate of Incorporation of Assertio Therapeutics, Inc. (Therapeutics), a wholly-owned subsidiary of the Company, to eliminate the pass-through voting provision that requires approval by both the Company and the Company’s stockholders prior to certain actions being taken by or at Therapeutics.
6.To ratify the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.
7.To transact such other business as may properly come before the meeting or any adjournments or postponements thereof.
|
| 2024-03-11 |
详情>>
业绩披露：
2023年年报每股收益-4.67美元,归母净利润-3.32亿美元,同比去年增长-402.8%
|
| 2023-11-08 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-4.35美元,归母净利润-2.75亿美元,同比去年增长-1402.95%
|
| 2023-04-03 |
股东大会：
将于2023-05-10召开股东大会
会议内容 ▼▲
- 1.To elect the five directors named in the Proxy Statement to hold office until the 2024 Annual Meeting of Stockholders or until their successors are duly elected and qualified.
2.To approve an amendment and restatement of the Company’s Amended and Restated 2014 Omnibus Incentive Plan to increase the number of shares available for issuance thereunder.
3.To approve, on an advisory basis, the compensation of the Company’s named executive officers.
4.To conduct, on an advisory basis, a vote on the preferred frequency of future advisory votes to approve the compensation of the Company’s named executive officers.
5.To approve of an amendment to the Amended and Restated Certificate of Incorporation of Assertio Therapeutics, Inc. (Therapeutics), a wholly-owned subsidiary of the Company, to eliminate the pass-through voting provision that requires approval by both the Company and the Company’s stockholders prior to certain actions being taken by or at Therapeutics.
6.To ratify the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
7.To transact such other business as may properly come before the meeting or any adjournments or postponements thereof.
|
| 2022-04-04 |
股东大会：
将于2022-05-04召开股东大会
会议内容 ▼▲
- 1.To elect the five directors named in the Proxy Statement to hold office until the 2023 Annual Meeting of Stockholders or until their successors are duly elected and qualified.
2.To approve an amendment and restatement of the Company’s Amended and Restated 2014 Omnibus Incentive Plan, including an increase in the number of shares available for issuance thereunder.
3.To approve, on an advisory basis, the compensation of the Company’s named executive officers.
4.To ratify the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022.
5.To transact such other business as may properly come before the meeting or any adjournments or postponements thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2020-04-20 |
股东大会：
将于2020-05-19召开股东大会
会议内容 ▼▲
- 1.To approve the issuance of shares of common stock, $0.0001 par value per share, of Assertio Holdings, Inc. ("Assertio Holdings Common Stock") in connection with the Merger with Zyla Life Sciences, as described in greater detail in Chapter I of this Joint Proxy Statement/Prospectus.
2.To elect the nine directors of Assertio named in the attached Joint Proxy Statement/Prospectus to serve until the 2021 Annual Meeting of Stockholders, or until their successors are duly elected and qualified.
3.To approve an increase in the number of shares available for issuance under Assertio's Amended and Restated 2014 Omnibus Incentive Plan, a copy of which is attached as Annex G to this Joint Proxy Statement/Prospectus. If the proposal to issue stock in connection with the Merger (Proposal 1) is not approved, the proposal to increase the number of shares available under Assertio's Amended and Restated 2014 Omnibus Incentive Plan will be automatically withdrawn.
4.To approve an increase in the number of shares available for issuance under Assertio's Amended and Restated 2004 Employee Stock Purchase Plan, a copy of which is attached as Annex H to this Joint Proxy Statement/Prospectus.
5.To approve an amendment to Assertio's certificate of incorporation to effect a reverse stock split at a ratio of not less than 1-for-2 and not greater than 1-for-4.
6.To approve, on an advisory basis, the compensation of Assertio's named executive officers.
7.To approve, on an advisory basis, Merger-related executive compensation arrangements.
8.To ratify the appointment of Ernst & Young LLP as Assertio's independent registered public accounting firm for the fiscal year ending December 31, 2020.
9.To approve the adjournment from time to time of the Assertio Annual Meeting if necessary to solicit additional proxies if there are not sufficient votes to adopt the proposal to issue stock in connection with the Merger (Proposal 1) at the time of the Assertio Annual Meeting or any adjournment or postponement thereof.
10.To transact such other business as may properly come before the Assertio Annual Meeting and any adjournments or postponements thereof.
|
| 2020-04-20 |
股东大会：
将于2020-05-19召开股东大会
会议内容 ▼▲
- 1.To consider and vote on a proposal to adopt the Agreement and Plan of Merger, dated as of March 16, 2020 (as it may be amended from time to time, referred to as the "Merger Agreement"), by and among Zyla, Assertio, Assertio Holdings, Merger Sub and Alligator Merger Sub, Inc., a Delaware corporation, a copy of which is attached as Annex A to this Joint Proxy Statement/Prospectus, which is referred to as the "Merger Agreement Proposal";
2.To consider and vote on a proposal to approve the adjournment from time to time of the Zyla Special Meeting if necessary to solicit additional proxies if there are not sufficient votes to adopt the Merger Agreement at the time of the Zyla Special Meeting or any adjournment or postponement thereof, which is referred to as the "Zyla Adjournment Proposal";
3.To consider and vote on a proposal to approve, on an advisory (non-binding) basis, the compensation that will or may be paid or provided by Zyla to its named executive officers in connection with the Merger which is referred to in this notice as the "Zyla Compensation Advisory Proposal".
|
| 2019-04-08 |
股东大会：
将于2019-05-07召开股东大会
会议内容 ▼▲
- 1.To elect the eight directors named in the Proxy Statement to hold office until the 2020 Annual Meeting of Stockholders and until their successors are elected and qualified.
2.To approve an increase in the number of shares available for issuance under the Company's Amended and Restated 2014 Omnibus Incentive Plan.
3.To approve, on an advisory basis, the compensation of the Company's named executive officers.
4.To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2019.
5.To transact such other business as may properly come before the meeting or any adjournments or postponements thereof.
|
| 2018-03-27 |
股东大会：
将于2018-05-08召开股东大会
会议内容 ▼▲
- 1.To elect the seven directors named in the Proxy Statement to hold office until the 2019 Annual Meeting of Shareholders and until their successors are elected and qualified.
2.To approve an increase in the number of shares available for issuance under the Company's Amended and Restated 2014 Omnibus Incentive Plan.
3.To approve a proposed change in corporate domicile from California to Delaware.
4.To approve a proposed change in the Company's name.
5.To approve, on an advisory basis, the compensation of the Company's named executive officers.
6.To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.
7.To vote on a shareholder proposal, if properly presented at the Annual Meeting, requesting that the Board of Directors prepare a report related to the monitoring and management of certain financial and reputational risks.
8.To transact such other business as may properly come before the meeting or any adjournments or postponements thereof.
|
| 2017-07-14 |
股东大会：
将于2017-08-15召开股东大会
会议内容 ▼▲
- 1.To elect the seven directors named in the Proxy Statement to hold office until the 2018 Annual Meeting of Shareholders and until their successors are elected and qualified.
2.To approve, on an advisory basis, the compensation of the Company's named executive officers.
3.To conduct, on an advisory basis, a vote on the preferred frequency of the future advisory votes to approve the compensation of the Company's named executive officers.
4.To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2017.
5.To transact such other business as may properly come before the meeting or any adjournments or postponements thereof.
|
| 2016-09-19 |
股东大会：
将于2016-11-15召开股东大会
|
| 2016-04-14 |
股东大会：
将于2016-05-18召开股东大会
会议内容 ▼▲
- 1.To reelect the six directors named in the Proxy Statement to hold office until the 2017 Annual Meeting of Shareholders and until their successors are elected and qualified.
2.To approve an increase in the number of shares available for issuance under the Company's Amended and Restated 2014 Omnibus Incentive Plan.
3.To approve an increase in the number of shares available for issuance under the Company's Amended and Restated 2004 Employee Stock Purchase Plan.
4.To approve, on an advisory basis, the compensation of the Company's named executive officers.
5.
To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2016.
6.
To transact such other business as may properly come before the meeting or any adjournments or postponements thereof.
|